Table 2.
The Bethesda system |
Surgery | Resection rate (%) | Histological diagnosis |
ROM at surgery (%) | Overall ROM (%) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytological diagnosis | No. (%) | AN | H | FA | FA oxy | Others | FTC | FTC oxy | PTC | PTC fol | PTC macrofol | PTC others | WDC-NOS | MTC | ATC | MALT | DLBCL | |||||
I | Inadequate | 382 (24) | 63 | 16.5 | 35 | 0 | 11 | 2 | 2 | 1 | 0 | 8 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 20.6 | 3.4 |
II | Benign | 626 (39) | 89 | 14.2 | 67 | 4 | 5 | 0 | 2 | 1 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 12.4 | 1.8 |
III | AUS | 171 (11) | 47 | 27.5 | 22 | 0 | 16 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 14.9 | 4.1 |
IV | Follicular neoplasm | 154 (9.6) | 85 | 55.2 | 21 | 0 | 26 | 17 | 0 | 12 | 2 | 0 | 2 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 24.7 | 13.6 |
V | Suspicious for malignancy | 52 (3.3) | 39 | 75 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 27 | 4 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 92.3 | 69.2 |
VI | Malignant | 215 (13) | 199 | 92.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 188 | 5 | 0 | 2 | 0 | 2 | 1 | 0 | 1 | 100 | 92.6 |
1,600 (100) | 522 | 32.6 | 148 | 4 | 58 | 21 | 4 | 15 | 2 | 231 | 15 | 2 | 7 | 2 | 3 | 1 | 7 | 2 | 55 | 17.9 | ||
Benign 235 | Malignant 287 |
FNA, fine-needle aspiration; AN, adenomatous nodule; H, Hashimoto’s thyroiditis; FA, follicular adenoma; FA oxy, oxyphilic follicular adenoma; FTC, follicular thyroid carcinoma; FTC oxy, follicular thyroid carcinoma, oxyphilic variant; PTC, papillary thyroid carcinoma; PTC fol, papillary thyroid carcinoma, follicular variant; PTC macrofol, papillary thyroid carcinoma, macrofollicular variant; WDC-NOS, well-differentiated carcinoma, not otherwise specified; MTC, medullary thyroid carcinoma; ATC, anaplastic thyroid carcinoma; MALT, mucosa-associated lymphoid tissue; DLBCL, diffuse large B-cell lymphoma; ROM, risk of malignancy; AUS, atypia of undetermined significance.